Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Appetite and EGFR[original query] |
|---|
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine 2010 Jun 362 (25): 2380-8. Maemondo Makoto, Inoue Akira, Kobayashi Kunihiko, Sugawara Shunichi, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Harada Masao, Yoshizawa Hirohisa, Kinoshita Ichiro, Fujita Yuka, Okinaga Shoji, Hirano Haruto, Yoshimori Kozo, Harada Toshiyuki, Ogura Takashi, Ando Masahiro, Miyazawa Hitoshi, Tanaka Tomoaki, Saijo Yasuo, Hagiwara Koichi, Morita Satoshi, Nukiwa Toshihiro, |
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
| Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer 2013 Aug 119 (16): 3043-51. Kwak Eunice L, Shapiro Geoffrey I, Cohen Seth M, Becerra Carlos R, Lenz Heinz-Josef, Cheng Wen-Fang, Su Wu-Chou, Robohn Meghan, Le Maulf Florence, Lobmeyer Maximilian T, Chand Vikram K, Iafrate A Jo |
| Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer research 2016 Sep 36 (9): 4951-4. Inomata Minehiko, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Yamada Toru, Miwa Toshiro, Hayashi Ryuji, Kashii Tatsuhiko, Matsui Shoko, Tobe Kazuyu |
| The Clinical and Mutational Spectrum of Turkish Patients with Cystinosis. Clinical journal of the American Society of Nephrology : CJASN 2017 8 12 (10): 1634-1641. Topaloglu Rezan, Gulhan Bora, ?nözü Mihriban, Canpolat Nur, Yilmaz Alev, Noyan Aytül, Dursun ?smail, Gökçe ?brahim, Gürgöze Metin Kaya, Akinci Nurver, Baskin Esra, Serdaro?lu Erkin, Demircio?lu Kiliç Beltinge, Yüksel Selçuk, Övünç Hacihamdio?lu Duygu, Korkmaz Emine, Hayran Mutlu, Ozaltin Fatih, |
| Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
| Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. Clinical lung cancer 2017 1 18 (4): 388-395.e4. Labbé Catherine, Leung Yvonne, Silva Lemes João Gabriel, Stewart Erin, Brown Catherine, Cosio Andrea Perez, Doherty Mark, O'Kane Grainne M, Patel Devalben, Cheng Nicholas, Liang Mindy, Gill Gursharan, Rett Alexandra, Naik Hiten, Eng Lawson, Mittmann Nicole, Leighl Natasha B, Bradbury Penelope A, Shepherd Frances A, Xu Wei, Liu Geoffrey, Howell Dor |
| Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer research and treatment 2019 Jul . Ahn Myung-Ju, Han Ji-Youn, Kim Dong-Wan, Cho Byoung Chul, Kang Jin-Hyoung, Kim Sang-We, Yang James Chih-Hsin, Mitsudomi Tetsuya, Lee Jong Se |
| A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of oncology : official journal of the European Society for Medical Oncology 2020 7 31 (10): 1397-1404. Park S, Lee M-H, Seong M, Kim S T, Kang J-H, Cho B C, Lee K H, Cho E K, Sun J-M, Lee S-H, Ahn J S, Park K, Ahn M |
| Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020 Oct 1078155220964895. Celik Emir, Samanci Nilay Sengul, Karadag Mehmet, Demirci Nebi Serkan, Cikman Duygu Ilke, Derin Sumeyra, Bedir Sahin, Degerli Ezgi, Oruc Kerem, Oztas Nihan Senturk, Demirelli Fuat Hulu |
| Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Jun . Akamatsu Hiroaki, Murakami Haruyasu, Harada Hideyuki, Shimizu Junichi, Hayashi Hidetoshi, Daga Haruko, Hasegawa Yoshikazu, Kim Young Hak, Kato Terufumi, Tokunaga Shoji, Nishimura Yasumasa, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
| Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer research 2021 1 41 (2): 911-917. Akamatsu Hiroaki, Ozawa Yuichi, Oyanagi Jun, Fujimoto Daichi, Hata Akito, Katakami Nobuyuki, Tomii Keisuke, Murakami Eriko, Sugimoto Takeya, Shimokawa Toshio, Koh Yasuhiro, Yamamoto Nobuyu |
| FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
| Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO open 2022 5 7 (3): 100473. Xing P, Zheng X, Wang Y, Chu T, Wang S, Jiang J, Qian J, Han X, Ding L, Wang Y, Cui L, Li H, Li L, Chen X, Han B, Hu P, Shi |
| Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
- Page last reviewed:Feb 1, 2023
- Page last updated:May 22, 2023
- Content source: